Close
FINDING CURES TOGETHER<sup>SM</sup>

Pancreatic Cancer: Advances in Science and Clinical Care

Program 

Friday, Sept. 6, 2019

Saturday, Sept. 7, 2019

Sunday, Sept. 8, 2019

Monday, Sept. 9, 2019


Friday, Sept. 6

Welcome and Keynote Addresses
Session Chair: Brian M. Wolpin, Dana-Farber Cancer Institute, Boston, Massachusetts
6-7:40 p.m.

Welcome from Cochairs

Welcome from Lead Supporters
Kerri Kaplan, Lustgarten Foundation, Woodbury, New York
Julie Fleshman, Pancreatic Cancer Action Network, Manhattan Beach, Califorina

Rising Star Keynote
Mechanisms and consequences of pancreatic cancer stromal evolution
Mara H. Sherman, Oregon Health and Science University, Portland, Oregon

Opening Keynote
Targeting innate immunity in pancreatic carcinoma
George Miller, New York University Langone Health Perlmutter Cancer Center, New York, New York


Poster Session A / Opening Reception

7:45-10 p.m.


Top of page


Saturday, Sept. 7

Continental Breakfast with Networking Roundtables
7:30-8:30 a.m.

  • Dafna Bar-Sagi
  • Stephanie Dougan
  • Elizabeth Jaffee

Plenary Session 1: Tumor Microenvironment
Session Chair: Ben Z. Stanger, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
8:30-10:15 a.m.

Immune contexture of human pancreatic cancer
Lisa M. Coussens, Oregon Health and Science University, Portland, Oregon

Regulatory T cell depletion causes compensatory immune suppression and accelerates pancreatic carcinogenesis
Marina Pasca Di Magliano, University of Michigan, Ann Arbor, Michigan

Heterocellular interactions in the tumor microenvironment
Claus Jorgensen, Cancer Research UK Manchester Centre, Manchester, United Kingdom

Senescence induction triggers vascular remodeling and new vulnerabilities to chemo- and immunotherapy in pancreas cancer*
Marcus Ruscetti, Memorial Sloan Kettering Cancer Center, New York, New York


Break

10:15-10:45 a.m.

Plenary Session 2: Genomics
Session Chair: Andrew Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts
10:45 a.m.-12:30 p.m.

Clonal evolution and progression of pancreatic cancer precursor lesions
Laura DeLong Wood, Johns Hopkins University, Baltimore, Maryland

Multimodal evolutionary dynamics of pancreatic cancer
Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, New York

Molecular subtypes: Bench to bedside
Jen Jen Yeh, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Loss of TET2 activity results in epigenetic instability and drives PDAC molecular subtypes*
Eric O'Neill, University of Oxford, Oxford, United Kingdom

A novel deaminase independent function of APOBEC3A catalyzes widespread chromosomal instability to drive an aggressive metastatic phenotype in pancreatic cancer*
Sonja Woermann, The University of Texas MD Anderson Cancer Center, Houston, Texas


Lunch (Provided)
12:45-1:45 p.m.

Poster Session B
1:30-3:30 p.m.

Plenary Session 3: Immunology
Session Chair: Elizabeth M. Jaffee, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
3:30-5:30 p.m.

Link between adaptive and innate immunity in pancreatic cancer
Stephanie K. Dougan, Dana-Farber Cancer Institute, Boston, Massachusetts

Immune cell signaling in human and mouse pancreas cancer
Aida Habtezion, Stanford University, Stanford, California

Targeting pancreatic cancer with TCR-engineered T cells
Phil D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, Washington

STING and TLR independent activation of T cell responses against pancreatic cancer using agonistic CD40 antibody*
Katelyn Byrne, University of Pennsylvania, Philadelphia, Pennsylvania

Autophagy facilitates immune evasion of pancreatic cancer through downregulation of MHC class I molecules*
Keisuke Yamamoto, New York University School of Medicine, New York, New York

Evening Off / Dinner on Own
5:30 p.m.


Top of page


Sunday, Sept. 8

Continental Breakfast with Networking Roundtables
7:30-8:30 a.m. 

  • Dafna Bar-Sagi
  • Lisa Coussens
  • Brian Wolpin
  • Rosie Sears
  • Robert H. Vonderheide


Plenary Session 4: Early-Stage Trials and Novel Treatment Combinations
Session Chair: Luis A. Diaz, Memorial Sloan Kettering Cancer Center, New York, New York
8:30-10:30 a.m.

CD40 immunotherapy for pancreatic cancer
Robert H. Vonderheide, University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania

Modulating the immune response with epigenetic agents
Nilofer S. Azad, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Title to be announced
Diane M. Simeone, New York University, New York, New York

Multimodal mapping of the tumor microenvironment in pancreatic ductal adenocarcinoma*
Eileen Carpenter, University of Michigan, Ann Arbor, Michigan

Phase I/II study of mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma*
Christine Alewine, National Cancer Institute, Bethesda, Maryland

Intratumoral T cell distribution in murine and patient pancreatic cancer correlates with tissue heterogeneity and survival*
Julienne Carstens, The University of Texas MD Anderson Cancer Center, Houston, Texas


Break
10:30-10:45 a.m.


Plenary Session 5: Ras and Oncogene Signaling
Session Chair: Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York
10:45 a.m.-12:30 p.m.

Deciphering the origins of PDAC development
Laura D. Attardi, Stanford University School of Medicine, Stanford, California

KRAS and environmental signals regulate MYC to drive lineage plasticity, pancreas cancer progression, and therapeutic resistance
Rosalie C. Sears, Oregon Health and Science University, Portland, Oregon

Wild-type KRAS in pancreatic cancer tumorigenesis
Gloria H. Su, Columbia University, New York, New York

KRas modulates pancreatic cancer cell metabolism and invasive potential through the lipase HSL*
Cody Rozeveld, Mayo Clinic, Rochester, Minnesota

Enhancing the effect of autophagy inhibition for pancreatic cancer treatment*
Kirsten Bryant, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina


Lunch (on Own)

12:45-2 p.m.

Plenary Session 6: Prevention and Early Detection
Session Chair: Anirban Maitra, The University of Texas MD Anderson Cancer Center, Houston, Texas
2-4 p.m.

Early detection of pancreatic cancer: Challenges and opportunities
Anirban Maitra

Retooling a blood-based biomarker into a theranostic agent
Jason S. Lewis, Memorial Sloan Kettering Cancer Center, New York, New York

Circulating tumor DNA in cancer diagnosis: Challenges and potential
Anne Marie O'Broin-Lennon, Johns Hopkins Hospital, Baltimore, Maryland

Evaluation of the implementation of genetic cancer screening guidelines in African American pancreatic cancer patients in a safety net hospital*
Taiwo Ajose, Morehouse School of Medicine, Atlanta, Georgia

The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice*
Dannielle Engle, Salk Institute for Biological Studies, La Jolla, California

Poster Session C / Reception
4-6:30 p.m.

Top of page

Monday, Sept. 9

Continental Breakfast
7-8 a.m.

Plenary Session 7: Metabolism
Session Chair: Alec C. Kimmelman, New York University Langone Medical Center, New York, New York
8-9:45 a.m.

Title to be announced
Matthew G. Vander Heiden, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts

New players and unique features of cancer lysosomes
Rushika M. Perera, University of California San Francisco, San Francisco, California

Identifying metabolic dependencies in pancreatic cancer
Alec C. Kimmelman

Targeting macrophage metabolism to improve therapy in pancreatic cancer*
Christopher Halbrook, University of Michigan, Ann Arbor, Michigan

Break
9:45-10 a.m.

Plenary Session 8: New Models, Systems, Animals, and Beyond
Session Chair: Tyler Jacks, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
10-11:45 a.m.

Modeling pancreatic cancer in the mouse
Tyler Jacks

Title to be announced
Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, New York

Investigating the immune microenvironment in mouse models of pancreatic cancer
Jen P. Morton, Cancer Research UK Beatson Institute, Glasgow, United Kingdom

Preclinical models to dissect immune escape in pancreatic cancer*
William Freed-Pastor, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts

Assessment of tumor heterogeneity, clonal evolution, and the stromal microenvironment in metastatic pancreatic ductal adenocarcinoma and matched patient-derived organoids*
Srivatsan Raghavan, Dana-Farber Cancer Institute, Boston, Massachusetts


Closing Keynote
11:45 a.m.-12:30 p.m.

Pancreatic cancer immunotherapy: Moving forward
Dung Thi Le, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Closing Remarks
Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York
12:30 p.m.

Top of page